(Total Views: 697)
Posted On: 02/06/2021 12:05:13 AM
Post# of 154606
“Maybe Pourhassan, Kelly, and the rest have studied the available experimental reports on leronlimab's suppression of PDL1 in cancer cells.”
Neither NP nor SK have the education, training, or experience to identify PDL1 as a target for leronlimab. None of leronlimab’s current indications were identified by NP or SK (not HIV, GvHD, cancer or COVID). I do not recall who identified NASH.
The good news is that CYDY is responsive to potential blockbuster indications for leronlimab, which means that they’ll likely pay for a pre-clinical study to evaluate the PDL1 science. Approval for COVID will fund these pre-clinical trials and phase 2 trials if the pre-clinical data is good.
Neither NP nor SK have the education, training, or experience to identify PDL1 as a target for leronlimab. None of leronlimab’s current indications were identified by NP or SK (not HIV, GvHD, cancer or COVID). I do not recall who identified NASH.
The good news is that CYDY is responsive to potential blockbuster indications for leronlimab, which means that they’ll likely pay for a pre-clinical study to evaluate the PDL1 science. Approval for COVID will fund these pre-clinical trials and phase 2 trials if the pre-clinical data is good.
(6)
(0)
